MedPath

Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity

Not Applicable
Conditions
Overweight and Obesity
Lupus Erythematosus
Interventions
Dietary Supplement: Vitamin B12 + folic acid supplementation
Dietary Supplement: Placebo supplementation
Registration Number
NCT05097365
Lead Sponsor
University of Sao Paulo
Brief Summary

Dietary supplementation with methyl donors has been demonstrated to increase DNA methylation in leucocytes whereas a limited dietary intake of methyl donors was associated with DNA hypomethylation. Considering SLE disease, previously study showed that high doses of vitamin B6 and folate were associated with less severe SLE. Furthermore, some evidences reported a relatively high incidence of decreased serum B12 levels in rheumatic patients. This led to the suggestion that diets rich in methyl group donors could have beneficial effects on SLE.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
Female
Target Recruitment
51
Inclusion Criteria

Not provided

Exclusion Criteria
  • Current infection
  • Diabetes
  • Arterial hypertension
  • Smokers
  • Pregnancy
  • Anticoagulants use
  • Methotrexate use
  • Other autoimmune diseases
  • Current vitamin B12 or/and folic acid supplementation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Supplemented Excess Body Weight GroupVitamin B12 + folic acid supplementationPatients with excess body weight (BMI \> 25 kg/m²) that will receive supplementation.
Control Normal Weight GroupPlacebo supplementationPatients with normal weight (BMI between 18.5 and 24.9 kg/m²) that will receive placebo.
Control Excess Body Weight GroupPlacebo supplementationPatients with excess body weight (BMI \> 25 kg/m²) that will receive placebo.
Supplemented Normal Weight GroupVitamin B12 + folic acid supplementationPatients with normal weight (BMI between 18.5 and 24.9 kg/m²) that will receive supplementation.
Primary Outcome Measures
NameTimeMethod
Change from baseline on serum vitamin B12 concentrations at 12 weeksBaseline and 12 weeks

Serum vitamin B12 concentrations in pg/mL

Change from baseline on DNA methylation profile at 12 weeksBaseline and 12 weeks

Percentage of DNA methylation level

Change from baseline on weight at 12 weeksBaseline and 12 weeks

Weight in kilograms

Change from baseline on serum folic acid concentrations at 12 weeksBaseline and 12 weeks

Serum folic acid concentrations in ng/mL

Secondary Outcome Measures
NameTimeMethod
Change from baseline on fat free mass at 12 weeksBaseline and 12 weeks

Fat free mass in kilograms

Change from baseline on STAT3 gene expression at 12 weeksBaseline and 12 weeks

Relative gene expression of STAT3

Duration of disease since diagnosisBaseline

Units of Measure: years

Change from baseline on miR-146 expression at 12 weeksBaseline and 12 weeks

Relative miR-146 expression

Change from baseline on miR-181 expression at 12 weeksBaseline and 12 weeks

Relative miR-181 expression

Change from baseline on miR-126 expression at 12 weeksBaseline and 12 weeks

Relative miR-126 expression

Change from baseline on LEP gene expression at 12 weeksBaseline and 12 weeks

Relative gene expression of LEP

Change from baseline on serum adipokines concentrations at 12 weeksBaseline and 12 weeks

Serum adipokines concentration in ng/mL

Change from baseline on serum triglycerides concentrations at 12 weeksBaseline and 12 weeks

Serum triglycerides concentration in mg/dL

Change from baseline on height at 12 weeksBaseline and 12 weeks

Height in meters

Age of onsetBaseline

Units of Measure: years

Change from baseline on miR-21 expression at 12 weeksBaseline and 12 weeks

Relative miR-21 expression

Change from baseline on TNF-a gene expression at 12 weeksBaseline and 12 weeks

Relative gene expression of TNF-a

Change from baseline on ADIPOQ gene expression at 12 weeksBaseline and 12 weeks

Relative gene expression of ADIPOQ

Change from baseline on MTHFR gene expression at 12 weeksBaseline and 12 weeks

Relative gene expression of MTHFR

Change from baseline on IL-6 gene expression at 12 weeksBaseline and 12 weeks

Relative gene expression of IL-6

Change from baseline on DNMT1 gene expression at 12 weeksBaseline and 12 weeks

Relative gene expression of DNMT1

Change from baseline on serum leptin concentrations at 12 weeksBaseline and 12 weeks

Serum leptin concentration in ng/mL

Change from baseline on serum IL-6 concentrations at 12 weeksBaseline and 12 weeks

Serum IL-6 concentration in ng/mL

Change from baseline on serum IL-17 concentrations at 12 weeksBaseline and 12 weeks

Serum IL-17 concentration in ng/mL

Change from baseline on serum IL-2 concentrations at 12 weeksBaseline and 12 weeks

Serum IL-2 concentration in ng/mL

Change from baseline on serum C-reactive protein concentrations at 12 weeksBaseline and 12 weeks

Serum C-reactive protein concentration in ng/mL

Change from baseline on serum cholesterol concentrations at 12 weeksBaseline and 12 weeks

Serum cholesterol concentrations in mg/dL

Change from baseline on abdominal circumference at 12 weeksBaseline and 12 weeks

Abdominal circumference in centimeters

Change from baseline on fat mass at 12 weeksBaseline and 12 weeks

Fat mass in kilograms

Change from baseline on serum glucose concentrations at 12 weeksBaseline and 12 weeks

Serum glucose concentrations in mg/dL

Change from baseline on dietary intake at 12 weeksBaseline and 12 weeks

Dietary intake in g and percentage

Change from baseline on serum TNF-a concentrations at 12 weeksBaseline and 12 weeks

Serum TNF-a concentration in ng/mL

Change from baseline on body mass index at 12 weeksBaseline and 12 weeks

Body mass index in kilograms/meters\^2

Trial Locations

Locations (1)

Univsersity of Sao Paulo

🇧🇷

Sao Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath